Many global biotech companies view China as a post-hoc commercial market, considering the country only in later stages of clinical development. This common oversight often forces costly bridging studies, extends development timelines and leaves much of China's R&D potential untapped.
That approach no longer aligns with today's development landscape. Over the past decade, China has grown from a commercial destination into a strategic engine for global drug development. For biotechs striving to compress timelines and lift R&D productivity, integrating China from the earliest planning phases delivers tangible improvements in trial speed, data robustness and cost-efficiency.
“Many biotechs are coming to us with questions about China, but often they are already at a stage where key development decisions have been made,” said George Li, Managing Director, China, Clinical Development, Syneos Health. “Sponsors are better positioned to capture far greater value when China is embedded within the global strategy early on, rather than added as a last-minute operational consideration.”
Drawing on more than 25 years of experience supporting global sponsors, George highlighted several factors that can help biotechs realize greater value from China in clinical development.
A changing regulatory landscape enables faster global trial participation
Since joining the ICH in 2017, China has implemented regulatory reforms that have shortened study start-up timelines and aligned local requirements with global development standards.
In 2018, the National Medical Products Administration (NMPA) and Center for Drug Evaluation (CDE) rolled out an implied IND pathway, allowing sponsors to proceed if no major objections are raised within 60 working days. Most recently, China introduced an accelerated 30-working-day review pathway for certain innovative therapies, helping streamline clinical development workflows.
These policy shifts have enabled China to participate earlier in global clinical programs. Sponsors that plan for China from day one can deploy parallel enrollment strategies and, in suitable settings, eliminate the need for standalone bridging trials. Proactive regulatory alignment and thoughtful protocol design can position China as a development accelerator rather than a late-stage consideration.
Large patient pools promise speed, yet execution defines success
Biotechs are consistently drawn to China’s enormous patient population and well-established tertiary hospital networks. The country provides access to one of the world’s largest patient pools across major therapeutic areas, including oncology, cardiometabolic disease and immunology. China records roughly 5 million new cancer cases annually, offering significant recruitment opportunities for oncology trials.
Raw patient volume alone cannot guarantee fast enrolment. High-performing clinical programs prioritize site quality over sheer quantity. Selecting experienced investigators and sites with proven patient access, strong infrastructure and operational capabilities is critical. Early investment in feasibility assessments, site selection and investigator engagement keeps recruitment on track throughout the study lifecycle.
China-generated data is gaining global regulatory confidence
China’s clinical research ecosystem has matured rapidly. A growing number of leading Chinese investigators now have extensive MRCT experience, and China’s adoption of ICH E17 principles supports prospective inclusion of Chinese cohorts in global studies.
Chinese sites are also increasingly experienced with international regulatory expectations and sponsor quality standards. Stronger infrastructure, greater clinical trial experience and increased exposure to global inspections have contributed to improved confidence in data reliability. To ensure China-generated data can be fully leveraged in global submissions, sponsors should align statistical plans, clinical endpoints and cross-regional trial frameworks at the design stage. This prevents costly protocol rework downstream and enables local data to contribute directly to global benefit-risk evidence packages.
Deep local expertise unlocks operational efficiency
For many resource-constrained biotechs, execution costs remain an important consideration. Relative to U.S. and Western European sites, China can deliver meaningful gains in site expenditures and enrolment velocity, depending on the therapeutic area and study complexity.
However, cost advantages can diminish without a clear understanding of local requirements. Sponsors should account for China-specific requirements related to ethics approvals, HGRAC, data privacy regulations, contracting, and site activation processes. In many cases, cost efficiency depends on more than lower operational costs. Real operational savings stem not merely from lower unit costs, but from navigating local rules efficiently while preserving consistent global quality and governance benchmarks.
Reconciling local on-the-ground delivery with global governance
Successful China strategies balance local expertise with global governance. Local clinical teams, regulatory experts and investigators provide critical knowledge of country-specific processes, healthcare systems and operational realities. Meanwhile, global teams safeguard consistency across protocol execution, quality standards and overarching regulatory strategy.
A well-defined governance framework connects these capabilities through clear accountability, centralized performance metrics, and regular cross-regional reviews. This approach allows sponsors to benefit from China’s operational strengths without compromising the quality and consistency required for global development programs.
Conclusion: Position China as a strategic accelerator, not an afterthought
When incorporated early and supported by the fit-for-purpose operating model, China can accelerate patient enrollment, generate globally valid data and improve development efficiency. The benefits come from forward-thinking study design, strategic site selection, proactive management of local requirements and a governance framework that connects regional execution with global objectives.
Sponsors capturing the greatest value from clinical opportunities in China have moved beyond debating whether to enter China. Instead, they focus on how early and how strategically China can be woven into global drug development roadmaps. This mindset benefits not only global biotech sponsors but also supports earlier patient access to innovative medicines.
